Stifel analyst Annabel Samimy reiterated a Buy rating and $26.00 price target on Cara Therapeutics (NASDAQ: CARA) following ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE